New sickle cell Drug's heart safety put to the test
NCT ID NCT07023029
Summary
This study tested whether a potential new medicine for sickle cell disease, called etavopivat, affects the heart's electrical activity in healthy people. It involved 33 healthy volunteers who received different doses of the drug, a placebo, or an approved comparison drug to check for any heart-related side effects. The main goal was to see if the drug is safe for the heart before testing it in people with sickle cell disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.